Go Pro
→ Could Your Bank Stop AI in Time? (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.21
-0.6%		$5.58
$3.27
▼
$7.26
$2.67B1.5520.40 million shs3.66 million shs
GLAS
Glass House Brands
$9.98
-0.3%		$0.00
$5.15
▼
$13.93
$803.52MN/A370,723 shs232,708 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
▼
$19.50
$2.86B1.21.02 million shsN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$17.80
$17.13
$6.93
▼
$20.22
$2.54B1.032.23 million shs1.32 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
-0.55%+0.42%+39.46%+70.05%+82.07%
GLAS
Glass House Brands
-0.51%-0.31%-14.50%+997,899,900.00%+997,899,900.00%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
0.00%-5.07%-0.22%+16.57%+143.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.21
-0.6%		$5.58
$3.27
▼
$7.26
$2.67B1.5520.40 million shs3.66 million shs
GLAS
Glass House Brands
$9.98
-0.3%		$0.00
$5.15
▼
$13.93
$803.52MN/A370,723 shs232,708 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
▼
$19.50
$2.86B1.21.02 million shsN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$17.80
$17.13
$6.93
▼
$20.22
$2.54B1.032.23 million shs1.32 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
-0.55%+0.42%+39.46%+70.05%+82.07%
GLAS
Glass House Brands
-0.51%-0.31%-14.50%+997,899,900.00%+997,899,900.00%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
0.00%-5.07%-0.22%+16.57%+143.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
2.20
Hold$10.5646.41% Upside
GLAS
Glass House Brands
2.67
Moderate Buy$17.0070.36% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3.00
Buy$26.7550.28% Upside

Current Analyst Ratings Breakdown

Latest GLAS, MOR, TRVI, and ATAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2026
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$12.00 ➝ $8.00
8/12/2026
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$8.00
8/7/2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$23.00
8/7/2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$24.00 ➝ $25.00
8/7/2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$40.00
8/7/2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$25.00 ➝ $30.00
7/20/2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$36.00
7/20/2026
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$7.45
7/20/2026
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/20/2026
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$25.00 ➝ $7.50
7/20/2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$4.09M649.02N/AN/A$0.69 per share10.45
GLAS
Glass House Brands
N/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/A$2.26 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
-$660.05M-$2.23N/AN/AN/A-19,019.44%-89.79%-63.58%N/A
GLAS
Glass House Brands
N/AN/AN/A71.28N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$42.76M-$0.34N/AN/AN/AN/A-23.59%-22.64%N/A

Latest GLAS, MOR, TRVI, and ATAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
-$0.1071-$0.09+$0.0171-$0.09$0.11 million$1.70 million
8/6/2026Q2 2026
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$0.1095-$0.11-$0.0005-$0.11N/AN/A
5/12/2026Q4 2025
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
-$0.11-$0.08+$0.03-$0.08$0.22 million$0.95 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
N/AN/AN/AN/AN/A
GLAS
Glass House Brands
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
N/AN/AN/A
GLAS
Glass House Brands
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/A
37.28
37.28

Institutional Ownership

CompanyInstitutional Ownership
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
28.41%
GLAS
Glass House Brands
N/A
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
95.76%

Insider Ownership

CompanyInsider Ownership
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
19.80%
GLAS
Glass House Brands
N/A
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
15.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
80368.17 million295.27 millionOptionable
GLAS
Glass House Brands
N/A80.27 millionN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
20142.48 million120.55 millionOptionable

Recent News About These Companies

What is HC Wainwright's Forecast for TRVI FY2030 Earnings?
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-forecast-for-trvi-fy2030-earnings-2026-08-12/
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A.
August 10 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-1525314-shares-in-trevi-therapeutics-inc-trvi-acquired-by-assenagon-asset-management-sa-2026-08-10/
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $30.00
August 10 at 2:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951645
Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/trevi-therapeutics-nasdaqtrvi-announces-earnings-results-hits-estimates-2026-08-07/
Trevi Therapeutics Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/trevi-therapeutics-q2-earnings-call-highlights-2026-08-07/
Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cantor-fitzgerald-forecasts-strong-price-appreciation-for-trevi-therapeutics-nasdaqtrvi-stock-2026-08-07/
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932576-trevi-therapeutics-inc-trvi-q2-2026-earnings-call-transcript
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340705/0/en/trevi-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-updates.html
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages
August 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30941793
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/trevi-therapeutics-inc-nasdaqtrvi-receives-average-rating-of-buy-from-analysts-2026-07-31/
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3336431/0/en/trevi-therapeutics-to-report-second-quarter-2026-financial-results-and-provide-a-corporate-update-on-august-6-2026.html
Trevi Therapeutics (TRVI) to Post Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/trevi-therapeutics-trvi-to-post-earnings-on-thursday-2026-07-30/
Trevi Therapeutics to Participate in Upcoming August Conferences
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334133/0/en/trevi-therapeutics-to-participate-in-upcoming-august-conferences.html
Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-trevi-therapeutics-inc-trvi-shares-sold-by-orbimed-advisors-llc-2026-07-27/
Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-octagon-capital-advisors-lp-reduces-stock-holdings-in-trevi-therapeutics-inc-trvi-2026-07-27/
Affinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVI
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-affinity-asset-advisors-llc-sells-150000-shares-of-trevi-therapeutics-inc-trvi-2026-07-25/
Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/trevi-therapeutics-nasdaqtrvi-downgraded-by-wall-street-zen-to-sell-2026-07-25/
Siren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVI
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-siren-llc-cuts-holdings-in-trevi-therapeutics-inc-trvi-2026-07-24/
Fifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVI
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-fifth-third-bancorp-invests-153-million-in-trevi-therapeutics-inc-trvi-2026-07-24/
Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/trevi-therapeutics-nasdaqtrvi-rating-increased-to-strong-buy-at-bmo-capital-markets-2026-07-22/
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/trevi-therapeutics-nasdaqtrvi-shares-down-51-heres-why-2026-07-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
SK hynix logo above a robotic arm placing memory chips on a wafer in a server data center.
Why SK hynix Could Be the Best AI Chip Stock to Buy Now
By Thomas Hughes | July 29, 2026
SK Hynix logo displayed on a lit panel inside a semiconductor manufacturing facility with robotic arms and equipment.
The SK Hynix IPO and 2027’s AI Memory Squeeze
By Jeffrey Neal Johnson | July 13, 2026
A semi-truck hauls a large cylindrical industrial component past police cars on a nighttime industrial roadway.
These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
By Nathan Reiff | July 28, 2026
Rows of server racks with blue network cables and storage drives in a data center aisle.
Which Storage Stock Is Best Positioned to Win the AI Memory War?
By Nathan Reiff | July 16, 2026
Data center at night with a labeled AI Compute Unit server rack and a technician working nearby.
5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest?
By Thomas Hughes | July 28, 2026
Atai Beckley stock logo

Atai Beckley NASDAQ:ATAI

$7.21 -0.04 (-0.55%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$7.22 +0.01 (+0.21%)
As of 08:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Glass House Brands NYSE:GLAS

$9.98 -0.03 (-0.31%)
Closing price 08/11/2026 03:59 PM Eastern
Extended Trading
$9.97 -0.01 (-0.13%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 08/10/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Trevi Therapeutics stock logo

Trevi Therapeutics NASDAQ:TRVI

$17.80 0.00 (0.00%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$17.80 +0.00 (+0.03%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas